← Back to headlines
Grail slides as trial misses primary endpoint, fails to show significant stage III-IV cancer reduction
GRAIL has reiterated its guidance for 22%-32% Galleri sales growth by 2026 and plans to expand its sales force following the NHS-Galleri trial.
20 Feb, 09:41 — 20 Feb, 09:41
Sources
Showing 1 of 1 sources
Related Stories
Manila Water prepares for summer heat and high demand
just now
Philippines Announces Results of April 2026 Physicians Licensure Examination
just now
Pagasa flags 2 areas for dangerous heat index levels on April 9
just now
Philippines Experiences High Heat Index, DOH Issues Warnings as Areas Log Danger Levels
just now